IBDEI0CS ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,5729,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5729,1,3,0)
 ;;=3^285.8
 ;;^UTILITY(U,$J,358.3,5729,1,4,0)
 ;;=4^ANEMIA NEC
 ;;^UTILITY(U,$J,358.3,5729,2)
 ;;=^87876
 ;;^UTILITY(U,$J,358.3,5730,0)
 ;;=282.2^^28^377^5
 ;;^UTILITY(U,$J,358.3,5730,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5730,1,3,0)
 ;;=3^282.2
 ;;^UTILITY(U,$J,358.3,5730,1,4,0)
 ;;=4^G6Pd DEFICIENCY
 ;;^UTILITY(U,$J,358.3,5730,2)
 ;;=^7225
 ;;^UTILITY(U,$J,358.3,5731,0)
 ;;=V08.^^28^377^6
 ;;^UTILITY(U,$J,358.3,5731,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5731,1,3,0)
 ;;=3^V08.
 ;;^UTILITY(U,$J,358.3,5731,1,4,0)
 ;;=4^HIV+ (ASYMPTOMATIC)
 ;;^UTILITY(U,$J,358.3,5731,2)
 ;;=^303392
 ;;^UTILITY(U,$J,358.3,5732,0)
 ;;=279.3^^28^377^7
 ;;^UTILITY(U,$J,358.3,5732,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5732,1,3,0)
 ;;=3^279.3
 ;;^UTILITY(U,$J,358.3,5732,1,4,0)
 ;;=4^IMMUNITY DEFICIENCY NOS
 ;;^UTILITY(U,$J,358.3,5732,2)
 ;;=^267969
 ;;^UTILITY(U,$J,358.3,5733,0)
 ;;=785.6^^28^377^8
 ;;^UTILITY(U,$J,358.3,5733,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5733,1,3,0)
 ;;=3^785.6
 ;;^UTILITY(U,$J,358.3,5733,1,4,0)
 ;;=4^LYMPHADENOPATHY
 ;;^UTILITY(U,$J,358.3,5733,2)
 ;;=^72368
 ;;^UTILITY(U,$J,358.3,5734,0)
 ;;=075.^^28^377^9
 ;;^UTILITY(U,$J,358.3,5734,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5734,1,3,0)
 ;;=3^075.
 ;;^UTILITY(U,$J,358.3,5734,1,4,0)
 ;;=4^MONONUCLEOSIS
 ;;^UTILITY(U,$J,358.3,5734,2)
 ;;=^62797
 ;;^UTILITY(U,$J,358.3,5735,0)
 ;;=238.4^^28^377^10
 ;;^UTILITY(U,$J,358.3,5735,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5735,1,3,0)
 ;;=3^238.4
 ;;^UTILITY(U,$J,358.3,5735,1,4,0)
 ;;=4^POLYCYTHEMIA VERA
 ;;^UTILITY(U,$J,358.3,5735,2)
 ;;=^304816
 ;;^UTILITY(U,$J,358.3,5736,0)
 ;;=282.49^^28^377^11
 ;;^UTILITY(U,$J,358.3,5736,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5736,1,3,0)
 ;;=3^282.49
 ;;^UTILITY(U,$J,358.3,5736,1,4,0)
 ;;=4^THALASSEMIA NEC
 ;;^UTILITY(U,$J,358.3,5736,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,5737,0)
 ;;=287.5^^28^377^12
 ;;^UTILITY(U,$J,358.3,5737,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5737,1,3,0)
 ;;=3^287.5
 ;;^UTILITY(U,$J,358.3,5737,1,4,0)
 ;;=4^THROMBOCYTOPENIA NOS
 ;;^UTILITY(U,$J,358.3,5737,2)
 ;;=^118988
 ;;^UTILITY(U,$J,358.3,5738,0)
 ;;=289.9^^28^377^13
 ;;^UTILITY(U,$J,358.3,5738,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5738,1,3,0)
 ;;=3^289.9
 ;;^UTILITY(U,$J,358.3,5738,1,4,0)
 ;;=4^THROMBOCYTOSIS
 ;;^UTILITY(U,$J,358.3,5738,2)
 ;;=^55344
 ;;^UTILITY(U,$J,358.3,5739,0)
 ;;=401.9^^28^378^1
 ;;^UTILITY(U,$J,358.3,5739,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5739,1,3,0)
 ;;=3^401.9
 ;;^UTILITY(U,$J,358.3,5739,1,4,0)
 ;;=4^HYPERTENSION NOS
 ;;^UTILITY(U,$J,358.3,5739,2)
 ;;=^186630
 ;;^UTILITY(U,$J,358.3,5740,0)
 ;;=401.1^^28^378^3
 ;;^UTILITY(U,$J,358.3,5740,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5740,1,3,0)
 ;;=3^401.1
 ;;^UTILITY(U,$J,358.3,5740,1,4,0)
 ;;=4^HYPERTENSION,BENIGN
 ;;^UTILITY(U,$J,358.3,5740,2)
 ;;=^269591
 ;;^UTILITY(U,$J,358.3,5741,0)
 ;;=401.0^^28^378^2
 ;;^UTILITY(U,$J,358.3,5741,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5741,1,3,0)
 ;;=3^401.0
 ;;^UTILITY(U,$J,358.3,5741,1,4,0)
 ;;=4^HYPERTENSION,ACCELERATED
 ;;^UTILITY(U,$J,358.3,5741,2)
 ;;=^73505
 ;;^UTILITY(U,$J,358.3,5742,0)
 ;;=227.0^^28^379^1
 ;;^UTILITY(U,$J,358.3,5742,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5742,1,3,0)
 ;;=3^227.0
 ;;^UTILITY(U,$J,358.3,5742,1,4,0)
 ;;=4^ADRENAL NEOPLASM,BENIGN
 ;;^UTILITY(U,$J,358.3,5742,2)
 ;;=^267688
 ;;^UTILITY(U,$J,358.3,5743,0)
 ;;=194.0^^28^379^2
 ;;^UTILITY(U,$J,358.3,5743,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5743,1,3,0)
 ;;=3^194.0
 ;;
 ;;$END ROU IBDEI0CS
